Immunogenicity and protective efficacy of recombinant fusion proteins containing spike protein of infectious bronchitis virus and hemagglutinin of H3N2 influenza virus in chickens
- PMID: 27497621
- PMCID: PMC7114550
- DOI: 10.1016/j.virusres.2016.07.010
Immunogenicity and protective efficacy of recombinant fusion proteins containing spike protein of infectious bronchitis virus and hemagglutinin of H3N2 influenza virus in chickens
Abstract
Infectious bronchitis (IB) is an acute and highly contagious viral respiratory disease of chickens and vaccination is the main method for disease control. The S1 protein, which contains several virus neutralization epitopes, is considered to be a target site of vaccine development. However, although protective immune responses could be induced by recombinant S1 protein, the protection rate in chickens was still low (<50%). Here, we generated fused S1 proteins with HA2 protein (rS1-HA2) or transmembrane domain and cytoplasmic tail (rS1-H3(TM)) from hemagglutinin of H3N2 influenza virus. After immunization, animals vaccinated with fusion proteins rS1-HA2 and rS1-H3(TM) demonstrated stronger robust humoral and cellular immune responses than that of rS1 and inactivated M41 vaccine. The protection rates of groups immunized with rS1-HA2 (87%) were significantly higher than the groups inoculated with rS1 (47%) and inactivated M41 vaccine (53%). And chickens injected with rS1-H3(TM) had similar level of protection (73%) comparing to chickens vaccinated with rS1 (47%) (P=0.07). Our data suggest that S1 protein fused to the HA2 or TM proteins from hemagglutinin of H3N2 influenza virus may provide a new strategy for high efficacy recombinant vaccine development against IBV.
Keywords: Fusion proteins; H3N2; IBV; Immunogenicity; S1 protein.
Copyright © 2016 Elsevier B.V. All rights reserved.
Figures




Similar articles
-
Recombinant Infectious Bronchitis Viruses Expressing Chimeric Spike Glycoproteins Induce Partial Protective Immunity against Homologous Challenge despite Limited Replication In Vivo.J Virol. 2018 Nov 12;92(23):e01473-18. doi: 10.1128/JVI.01473-18. Print 2018 Dec 1. J Virol. 2018. PMID: 30209177 Free PMC article.
-
Development and immunogenic potentials of chitosan-saponin encapsulated DNA vaccine against avian infectious bronchitis coronavirus.Microb Pathog. 2020 Dec;149:104560. doi: 10.1016/j.micpath.2020.104560. Epub 2020 Oct 14. Microb Pathog. 2020. PMID: 33068733 Free PMC article.
-
BacMam virus-based surface display of the infectious bronchitis virus (IBV) S1 glycoprotein confers strong protection against virulent IBV challenge in chickens.Vaccine. 2014 Feb 3;32(6):664-70. doi: 10.1016/j.vaccine.2013.12.006. Epub 2013 Dec 14. Vaccine. 2014. PMID: 24342247
-
Production and immunogenicity of chimeric virus-like particles containing the spike glycoprotein of infectious bronchitis virus.J Vet Sci. 2014;15(2):209-16. doi: 10.4142/jvs.2014.15.2.209. Epub 2013 Dec 27. J Vet Sci. 2014. PMID: 24378590 Free PMC article.
-
The avian coronavirus spike protein.Virus Res. 2014 Dec 19;194:37-48. doi: 10.1016/j.virusres.2014.10.009. Epub 2014 Oct 17. Virus Res. 2014. PMID: 25451062 Free PMC article. Review.
Cited by
-
A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin.J Biomol Struct Dyn. 2021 May;39(8):3025-3033. doi: 10.1080/07391102.2020.1754293. Epub 2020 Apr 22. J Biomol Struct Dyn. 2021. PMID: 32274964 Free PMC article. Review.
-
Construction and efficacy of a recombinant QX-like infectious bronchitis virus vaccine strain.Virus Genes. 2025 Jun;61(3):355-364. doi: 10.1007/s11262-025-02140-8. Epub 2025 Feb 27. Virus Genes. 2025. PMID: 40014292
-
Salmonella typhimurium Vaccine Candidate Delivering Infectious Bronchitis Virus S1 Protein to Induce Protection.Biomolecules. 2024 Jan 20;14(1):133. doi: 10.3390/biom14010133. Biomolecules. 2024. PMID: 38275762 Free PMC article.
-
Protection against infectious bronchitis virus by spike ectodomain subunit vaccine.Vaccine. 2017 Oct 13;35(43):5864-5871. doi: 10.1016/j.vaccine.2017.09.013. Epub 2017 Sep 9. Vaccine. 2017. PMID: 28899630 Free PMC article.
References
-
- Cavanagh D., Davis P.J., Pappin D.J., Binns M.M., Boursnell M.E., Brown T.D. Coronavirus IBV: partial amino terminal sequencing of spike polypeptide S2 identifies the sequence Arg-Arg-Phe-Arg-Arg at the cleavage site of the spike precursor propolypeptide of IBV strains Beaudette and M41. Virus Res. 1986;4(2):133–143. - PMC - PubMed
-
- Cavanagh D., Davis P.J., Darbyshire J.H., Peters R.W. Coronavirus IBV: virus retaining spike glycopolypeptide S2 but not S1 is unable to induce virus-neutralizing or haemagglutination-inhibiting antibody, or induce chicken tracheal protection. J. Gen. Virol. 1986;67(Pt. 7):1435–1442. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous